Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome–Positive B-Cell Precursor Acute Lymphoblastic Leukemia (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-589; Location: LEVEL 3, HALL B3; P1 | "Olverembatinib plus blinatumomab shows promising activity in patients with R/R Ph+ BCP-ALL or CML-LBP, with encouraging response rates and MRD clearance, and is generally well tolerated. The data support further investigation of this chemotherapy-free approach. AEs: adverse events, ALL: acute lymphoblastic leukemia, CML-LBP: lymphoid-blast-phase chronic myeloid leukemia, CR: complete response, DLT: dose-limiting toxicity, R/R Ph+ BCP-ALL: relapsed/refractory Philadelphia chromosome–positive B-cell precursor ALL, MRD: measurable residual disease, TKI: tyrosine kinase inhibitor."
Clinical • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1
|
|
Elias Jabbour 1; Maria R. Baer 2; Anthony M. Hunter 3; Dennis Kim 4; Vivian G. Oehler 5; Huanshan Guo 6; Zhihong Yang 7; Tommy Fu 7; Dajun Yang 7,8,9; Yifan Zhai 6,7,8; Hagop Kantarjian 1
|